Bispecific fusion antibodies with enhanced serum half-life

Details Bispecific fusion antibodies with enhanced serum half-life Bispecific fusion antibodies with enhanced serum half-life

C - Chemistry, Metallurgy

07

K

C07K 16/46 (2006.01) A61K 47/48 (2006.01) C07K 16/44 (2006.01)

Patent

CA 2569240

Drug compositions, fusions and conjugates are provided. The drug fusions and conjugates contain a therapeutic or diagnostic agent that is fused or conjugated to an antigen-binding fragment of an antibody that binds serum albumin. The drug compositions, fusions and conjugates have a longer in vivo half-life in comparison with the unconjugated or unfused therapeutic or diagnostic agent.

L'invention concerne des compositions de médicaments, des fusions et des conjugués. Ces fusions de médicaments et ces conjugués contiennent un agent thérapeutique ou diagnostique qui est fondu ou conjugué à un fragment se liant à un antigène d'anticorps qui se lie au sérum-albumine. Les compositions de médicaments, les fusions et les conjugués présentent une demi- vie in vivo plus longue que celle de l'agent thérapeutique ou diagnostique non conjugué ou non fondu.

Affiliated with

Also associated with

Rating

Bispecific fusion antibodies with enhanced serum half-life does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bispecific fusion antibodies with enhanced serum half-life, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bispecific fusion antibodies with enhanced serum half-life will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1425932